LAMA2 (Laminin subunit alpha-2) variants and mutations
LAMA2 (also known as Laminin subunit alpha-2) is a human protein-coding gene encoding a laminin subunit alpha-2 protein. It links cells to surrounding extracellular matrix through dystroglycan and integrins. Biallelic loss-of-function variants cause LAMA2-related muscular dystrophy, ranging from severe congenital disease to later-onset limb-girdle weakness. This analysis covers 4,740 LAMA2 variants and mutations. Of these, 72% have computational variant effect predictions. Disease context includes Congenital muscular dystrophy type 1A, congenital merosin-deficient muscular dystrophy 1A, and muscular dystrophy, limb-girdle, autosomal recessive 23. Example LAMA2 variants include M1T, P2R, and P2S.
Variant analysis overview
- Gene: LAMA2
- Protein: Laminin subunit alpha-2
- UniProt accession: P24043
- Organism: Homo sapiens
- Variants analyzed: 4740
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 4,495 unspecified-consequence records; 131 missense variants; 77 synonymous variants; 7 stop-gained variants; 22 frameshift variants; 5 in-frame deletions; 3 splice-region variants; 2 in-frame insertions
- Prediction scores: 3,422 variants have prediction scores (72% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Congenital muscular dystrophy type 1A, congenital merosin-deficient muscular dystrophy 1A, muscular dystrophy, limb-girdle, autosomal recessive 23, LAMA2-related muscular dystrophy, congenital muscular dystrophy, congenital muscular dystrophy due to LMNA mutation, laminin alpha 2-related dystrophy, hereditary disease, Abnormality of the musculature, eye disorder, qualitative or quantitative defects of merosin, myopia.
Protein structure and variant hotspots
- Protein features: 27 domains; 28 post-translational modification sites.
- Structural context: 3,629 variants have structural context.
- PTM context: 38 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable LAMA2 variants
Examples include M1T, P2R, P2S, P2L, P2P, G3E, G3R, G3*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs374403765, ClinGen CA147234456, ClinVar RCV000532735, ClinVar RCV000672881, MetaLR 0.10, MetaSVM -1.00, Pathogenic/Likely pathogenic, Merosin deficient congenital muscular dystrophy; Muscular dystrophy, limb-girdle
- P2R (p.Pro2Arg), rs1247617026, ClinGen CA365828168, ClinVar RCV001295366, ClinVar RCV005652591, REVEL 0.11, CADD 23.70, Uncertain significance, Inborn genetic diseases; LAMA2-related muscular dystrophy
- P2S (p.Pro2Ser), gnomAD rs1201494412, REVEL 0.08, CADD 20.30
- P2L (p.Pro2Leu), gnomAD 6-128883250-C-T, REVEL 0.03, CADD 23.50
- P2P (p.Pro2Pro), gnomAD 6-128883251-G-T, CADD 5.55
- G3E (p.Gly3Glu), NCI-TCGA TCGA novel, REVEL 0.06, CADD 22.50, Variant assessed as somatic; moderate impact.
- G3R (p.Gly3Arg), rs761472320, ClinGen CA3992190, ClinVar RCV002611783, ExAC rs761472320, REVEL 0.08, CADD 22.70, Uncertain significance, LAMA2-related muscular dystrophy
- G3* (p.Gly3Ter), gnomAD 6-128883252-G-T, CADD 35.00
- G3G (p.Gly3Gly), gnomAD 6-128883254-A-C, CADD 12.20
- A4D (p.Ala4Asp), gnomAD 6-128883256-C-A, REVEL 0.06, CADD 18.30
- A4V (p.Ala4Val), gnomAD 6-128883256-C-T, REVEL 0.06, CADD 17.00
- A4A (p.Ala4Ala), gnomAD 6-128883257-C-T, CADD 10.50
- A5S (p.Ala5Ser), rs367622987, ClinGen CA3992191, ClinVar RCV001090686, ClinVar RCV002554817, REVEL 0.04, CADD 17.00, Conflicting interpretations, Inborn genetic diseases; LAMA2-related muscular dystrophy; not provided
- A5T (p.Ala5Thr), rs367622987, ClinGen CA238603, ClinVar RCV000173131, ClinVar RCV000818174, REVEL 0.06, CADD 18.80, Conflicting interpretations, LAMA2-related muscular dystrophy; not provided
- A5D (p.Ala5Asp), gnomAD 6-128883259-C-A, REVEL 0.06, CADD 22.40
- A5A (p.Ala5Ala), rs574296023, gnomAD 6-128883260-C-T, CADD 14.80
- G6R (p.Gly6Arg), ExAC rs779529626, TOPMed rs779529626, REVEL 0.01, CADD 12.90
- G6V (p.Gly6Val), NCI-TCGA Cosmic COSV7035, cosmic curated COSV70350, REVEL 0.06, CADD 16.20, Variant assessed as somatic; moderate impact.
- G6W (p.Gly6Trp), gnomAD 6-128883261-G-T, REVEL 0.02, CADD 16.80
- G6G (p.Gly6Gly), rs1466207194, gnomAD 6-128883263-G-T, CADD 13.20
- V7A (p.Val7Ala), TOPMed rs1397324947, gnomAD rs1397324947, REVEL 0.02, CADD 17.10
- V7G (p.Val7Gly), TOPMed rs1397324947, gnomAD rs1397324947
- V7S (p.Val7Ser), gnomAD 6-128883260-CG-C, CADD 22.60
- V7F (p.Val7Phe), gnomAD 6-128883264-G-T, REVEL 0.02, CADD 18.00
- V7I (p.Val7Ile), gnomAD 6-128883264-G-A, REVEL 0.02, CADD 15.80
- L8F (p.Leu8Phe), TOPMed rs957189805, REVEL 0.03, CADD 16.50
- L8V (p.Leu8Val), TOPMed rs957189805, REVEL 0.01, CADD 16.20
- L8R (p.Leu8Arg), gnomAD 6-128883268-T-G, REVEL 0.25, CADD 23.50
- L8L (p.Leu8Leu), rs751119966, gnomAD 6-128883269-C-T, CADD 9.81
- L9F (p.Leu9Phe), TOPMed rs1775911631
- L9H (p.Leu9His), rs915657383, ClinGen CA147234470, ClinVar RCV003011349, Ensembl rs915657383, AlphaMissense 0.34, MetaLR 0.03, Uncertain significance, LAMA2-related muscular dystrophy
- L10F (p.Leu10Phe), rs754627719, ClinGen CA3992195, ClinVar RCV003577818, ExAC rs754627719, REVEL 0.04, CADD 20.90, Likely benign, LAMA2-related muscular dystrophy
- L10H (p.Leu10His), rs2482366909, ClinGen CA365828208, ClinVar RCV003340951, Uncertain significance, Muscular dystrophy, limb-girdle, autosomal recessive 23
- L10I (p.Leu10Ile), NCI-TCGA TCGA novel, REVEL 0.03, CADD 19.40, Variant assessed as somatic; moderate impact.
- L10L (p.Leu10Leu), rs886061038, gnomAD 6-128883275-T-G, CADD 10.70
- L11P (p.Leu11Pro), rs730880252, ClinGen CA273738, ClinVar RCV000157587, ClinVar RCV002469031, AlphaMissense 0.22, MetaLR 0.06, Uncertain significance, LAMA2-related muscular dystrophy; not provided
- L11M (p.Leu11Met), gnomAD 6-128883276-C-A, REVEL 0.13, CADD 24.10
- L11L (p.Leu11Leu), gnomAD 6-128883278-G-T, CADD 12.40
- L12Q (p.Leu12Gln), ExAC rs780670230, gnomAD rs780670230, REVEL 0.25, CADD 27.00
- L12C (p.Leu12Cys), rs1775913080, gnomAD 6-128883278-GC-G, CADD 27.20
- L12L (p.Leu12Leu), gnomAD 6-128883279-C-T, CADD 13.70
- L12M (p.Leu12Met), gnomAD 6-128883279-C-A, REVEL 0.18, CADD 23.70
- L12P (p.Leu12Pro), gnomAD 6-128883280-T-C, REVEL 0.32, CADD 27.70
- L12R (p.Leu12Arg), gnomAD 6-128883280-T-G, REVEL 0.27, CADD 27.30
- L13del (p.Leu13del), rs1347823295, gnomAD 6-128883264-GTCC-, CADD 15.40
- L13F (p.Leu13Phe), gnomAD 6-128883282-C-T, REVEL 0.11, CADD 23.10
- L13I (p.Leu13Ile), gnomAD 6-128883282-C-A, REVEL 0.10, CADD 19.00
- L13L (p.Leu13Leu), gnomAD 6-128883284-C-T, CADD 7.71
- S14F (p.Ser14Phe), gnomAD 6-128883286-C-T, REVEL 0.05, CADD 15.70
- S14Y (p.Ser14Tyr), gnomAD 6-128883286-C-A, REVEL 0.04, CADD 14.70
- S14S (p.Ser14Ser), rs1324008369, gnomAD 6-128883287-C-A, CADD 4.49
- G15R (p.Gly15Arg), TOPMed rs1330272710, gnomAD rs1330272710, NCI-TCGA Cosmic COSV1013, cosmic curated COSV10137, REVEL 0.06, CADD 16.30, Variant assessed as somatic; moderate impact.
- G15* (p.Gly15Ter), gnomAD 6-128883288-G-T, CADD 33.00
- G15A (p.Gly15Ala), gnomAD 6-128883289-G-C, REVEL 0.03, CADD 14.90
- G15V (p.Gly15Val), gnomAD 6-128883289-G-T, REVEL 0.07, CADD 20.10
- G15G (p.Gly15Gly), gnomAD 6-128883290-A-T, CADD 9.82
- G16A (p.Gly16Ala), TOPMed rs1433923964, gnomAD rs1433923964, REVEL 0.01, CADD 0.15, Uncertain significance
- G16D (p.Gly16Asp), rs1433923964, ClinGen CA365828239, ClinVar RCV000690212, TOPMed rs1433923964, REVEL 0.04, CADD 1.95, Uncertain significance, LAMA2-related muscular dystrophy
- G16S (p.Gly16Ser), gnomAD 6-128883291-G-A, REVEL 0.04, CADD 7.94
- G16C (p.Gly16Cys), gnomAD 6-128883291-G-T, REVEL 0.04, CADD 11.90
- G16V (p.Gly16Val), gnomAD 6-128883292-G-T, REVEL 0.03, CADD 1.72
- G16G (p.Gly16Gly), gnomAD 6-128883293-C-A, CADD 5.51
- p.Leu17 Gly19del, rs1775914260, gnomAD 6-128883290-AGGCC, CADD 15.30
- L17F (p.Leu17Phe), gnomAD 6-128883294-C-T, REVEL 0.03, CADD 15.30
- L17I (p.Leu17Ile), gnomAD 6-128883294-C-A, REVEL 0.01, CADD 14.30
- L17L (p.Leu17Leu), gnomAD 6-128883296-C-T, CADD 8.54
- G18E (p.Gly18Glu), Ensembl rs1562796409, REVEL 0.01, CADD 14.00
- G18R (p.Gly18Arg), rs747860244, ClinGen CA365828249, ClinVar RCV002624658, ExAC rs747860244, REVEL 0.14, CADD 15.90, Uncertain significance, LAMA2-related muscular dystrophy
- G18W (p.Gly18Trp), ExAC rs747860244, TOPMed rs747860244, gnomAD rs747860244, REVEL 0.18, CADD 23.60, Uncertain significance
- G18V (p.Gly18Val), gnomAD 6-128883298-G-T, REVEL 0.02, CADD 14.80
- G18G (p.Gly18Gly), gnomAD 6-128883299-G-T, CADD 9.19
- G19D (p.Gly19Asp), TOPMed rs1775916031, gnomAD rs1775916031, REVEL 0.02, CADD 2.53
- G19V (p.Gly19Val), TOPMed rs1775916031, gnomAD rs1775916031, REVEL 0.02, CADD 6.37
- G19A (p.Gly19Ala), gnomAD 6-128883296-CG-C, CADD 23.10
- G19C (p.Gly19Cys), gnomAD 6-128883300-G-T, REVEL 0.07, CADD 21.90
- G19S (p.Gly19Ser), gnomAD 6-128883300-G-A, REVEL 0.05, CADD 17.50
- G19G (p.Gly19Gly), rs771141152, gnomAD 6-128883302-C-T, CADD 8.66
- V20A (p.Val20Ala), rs746372774, ClinGen CA3992200, ClinVar RCV001317544, ClinVar RCV003132406, REVEL 0.00, CADD 5.67, Uncertain significance, Inborn genetic diseases; LAMA2-related muscular dystrophy; not provided
- V20I (p.Val20Ile), ExAC rs779423546, TOPMed rs779423546, REVEL 0.01, CADD 5.81
- V20L (p.Val20Leu), ExAC rs779423546, TOPMed rs779423546, REVEL 0.02, CADD 6.05
- V20R (p.Val20Arg), gnomAD 6-128883296-C-CG, CADD 24.10
- V20V (p.Val20Val), gnomAD 6-128883305-A-G, CADD 6.71
- Q21* (p.Gln21Ter), rs886061039, ClinGen CA365828264, ClinVar RCV000673285, ClinVar RCV002531335, CADD 33.00, Pathogenic
- Q21E (p.Gln21Glu), rs886061039, ClinGen CA10621354, ClinVar RCV000327749, TOPMed rs886061039, REVEL 0.02, CADD 7.18, Uncertain significance, Congenital muscular dystrophy due to partial LAMA2 deficiency
- Q21R (p.Gln21Arg), rs1775917787, ClinGen CA365828266, ClinVar RCV001156177, Ensembl rs1775917787, REVEL 0.01, CADD 6.50, Uncertain significance, Congenital muscular dystrophy due to partial LAMA2 deficiency
- Q21K (p.Gln21Lys), gnomAD 6-128883306-C-A, REVEL 0.01, CADD 5.49
- Q21L (p.Gln21Leu), gnomAD 6-128883307-A-T, REVEL 0.02, CADD 10.20
- Q21Q (p.Gln21Gln), rs772763260, gnomAD 6-128883308-G-A, CADD 6.78
- Q21H (p.Gln21His), gnomAD 6-128883308-G-T, REVEL 0.02, CADD 12.20
- A22E (p.Ala22Glu), NCI-TCGA Cosmic COSV7035, cosmic curated COSV70353, REVEL 0.03, CADD 8.74, Variant assessed as somatic; moderate impact.
- A22R (p.Ala22Arg), gnomAD 6-128883307-AG-A, CADD 20.40
- A22S (p.Ala22Ser), gnomAD 6-128883309-G-T, REVEL 0.03, CADD 8.37
- A22A (p.Ala22Ala), gnomAD 6-128883311-G-A, CADD 7.12
- Q23* (p.Gln23Ter), rs2482367178, ClinGen CA365828278, ClinVar RCV002872162, CADD 35.00, Pathogenic
- Q23L (p.Gln23Leu), NCI-TCGA TCGA novel, REVEL 0.18, CADD 21.50, Variant assessed as somatic; moderate impact.
- Q23R (p.Gln23Arg), gnomAD rs1212121600, REVEL 0.09, CADD 19.10
- Q23K (p.Gln23Lys), gnomAD 6-128883312-C-A, REVEL 0.09, CADD 17.20
- Q23H (p.Gln23His), gnomAD 6-128883314-G-T, REVEL 0.12, CADD 22.90
- Q23Q (p.Gln23Gln), gnomAD 6-128883314-G-A, CADD 10.00
- R24G (p.Arg24Gly), rs868408509, ClinGen CA365828284, ClinVar RCV001756333, ClinVar RCV001882815, REVEL 0.04, CADD 15.80, Uncertain significance, Inborn genetic diseases; LAMA2-related muscular dystrophy; not provided
- R24L (p.Arg24Leu), gnomAD rs1451385109, REVEL 0.04, CADD 14.20
- R24W (p.Arg24Trp), rs868408509, cosmic curated COSV10973, TOPMed rs868408509, gnomAD rs868408509, REVEL 0.12, CADD 18.40, Uncertain significance
- R24R (p.Arg24Arg), gnomAD 6-128883315-C-A, CADD 10.20
- R24Q (p.Arg24Gln), gnomAD 6-128883316-G-A, REVEL 0.03, CADD 15.30
- P25L (p.Pro25Leu), rs145310035, ClinGen CA3992202, ClinVar RCV000514861, ClinVar RCV001083278, REVEL 0.03, CADD 9.22, Conflicting interpretations, Inborn genetic diseases; LAMA2-related muscular dystrophy; Congenital muscular d
- P25Q (p.Pro25Gln), 1000Genomes rs145310035, ESP rs145310035, ExAC rs145310035, TOPMed rs145310035, REVEL 0.03, CADD 6.19, Benign
- P25T (p.Pro25Thr), gnomAD 6-128883318-C-A, REVEL 0.01, CADD 2.63
- P25S (p.Pro25Ser), gnomAD 6-128883318-C-T, REVEL 0.01, CADD 1.98
- P25P (p.Pro25Pro), gnomAD 6-128883320-G-A, CADD 7.15
- Q26* (p.Gln26Ter), ExAC rs768810174, gnomAD rs768810174, CADD 34.00
- Q26P (p.Gln26Pro), gnomAD rs1265619810, REVEL 0.03, CADD 8.67
- Q26K (p.Gln26Lys), gnomAD 6-128883321-C-A, REVEL 0.04, CADD 9.24
- Q26R (p.Gln26Arg), gnomAD 6-128883322-A-G, REVEL 0.01, CADD 7.44
- Q26L (p.Gln26Leu), gnomAD 6-128883322-A-T, REVEL 0.02, CADD 9.69
- Q26H (p.Gln26His), gnomAD 6-128883323-G-T, REVEL 0.05, CADD 18.20
- Q26Q (p.Gln26Gln), gnomAD 6-128883323-G-A, CADD 8.88
- Q27R (p.Gln27Arg), gnomAD rs1775919678, REVEL 0.01, CADD 6.24
- Q27K (p.Gln27Lys), gnomAD 6-128883324-C-A, REVEL 0.02, CADD 10.80
- Q27* (p.Gln27Ter), gnomAD 6-128883324-C-T, CADD 35.00
- Q27L (p.Gln27Leu), gnomAD 6-128883325-A-T, REVEL 0.01, CADD 11.50
- Q27H (p.Gln27His), gnomAD 6-128883326-G-T, REVEL 0.05, CADD 10.90
- Q27Q (p.Gln27Gln), rs1478239434, gnomAD 6-128883326-G-A, CADD 6.83
- Q28* (p.Gln28Ter), ExAC rs776665392, gnomAD rs776665392, CADD 35.00
- Q28E (p.Gln28Glu), ExAC rs776665392, gnomAD rs776665392, REVEL 0.08, CADD 6.07
- Q28del (p.Gln28del), gnomAD 6-128883319-CGCA-, CADD 10.60
- Q28K (p.Gln28Lys), gnomAD 6-128883327-C-A, REVEL 0.13, CADD 8.13
- Q28R (p.Gln28Arg), gnomAD 6-128883328-A-G, REVEL 0.01, CADD 0.98
- Q28L (p.Gln28Leu), gnomAD 6-128883328-A-T, REVEL 0.02, CADD 4.64
- Q28Q (p.Gln28Gln), gnomAD 6-128883329-G-A, CADD 7.18
- Q28H (p.Gln28His), gnomAD 6-128883329-G-T, REVEL 0.03, CADD 11.50
- R29W (p.Arg29Trp), NCI-TCGA TCGA novel, REVEL 0.07, CADD 21.90, Variant assessed as somatic; moderate impact.
- R29R (p.Arg29Arg), rs762102801, gnomAD 6-128883330-C-A, CADD 10.10
- R29L (p.Arg29Leu), gnomAD 6-128883331-G-T, REVEL 0.05, CADD 22.90
- R29Q (p.Arg29Gln), gnomAD 6-128883331-G-A, REVEL 0.02, CADD 19.90
- R29P (p.Arg29Pro), gnomAD 6-128883331-G-C, REVEL 0.23, CADD 23.10
- Q30H (p.Gln30His), ESP rs371739718, ExAC rs371739718, TOPMed rs371739718, gnomAD rs371739718, REVEL 0.05, CADD 18.60
- Q30K (p.Gln30Lys), gnomAD 6-128883333-C-A, REVEL 0.05, CADD 12.80
- Q30* (p.Gln30Ter), gnomAD 6-128883333-C-T, CADD 36.00
- Q30R (p.Gln30Arg), gnomAD 6-128883334-A-G, REVEL 0.02, CADD 13.70
- Q30L (p.Gln30Leu), gnomAD 6-128883334-A-T, REVEL 0.03, CADD 16.50
- Q30Q (p.Gln30Gln), gnomAD 6-128883335-G-A, CADD 9.50
- S31A (p.Ser31Ala), Ensembl rs1582593248
- S31P (p.Ser31Pro), gnomAD 6-128883336-T-C, REVEL 0.01, CADD 9.49
- S31* (p.Ser31Ter), gnomAD 6-128883337-C-G, CADD 32.00
- S31L (p.Ser31Leu), gnomAD 6-128883337-C-T, REVEL 0.01, CADD 13.20
- S31S (p.Ser31Ser), gnomAD 6-128883338-A-G, CADD 6.46
- Q32* (p.Gln32Ter), Ensembl rs1775921049, CADD 36.00, Likely pathogenic
- Q32H (p.Gln32His), TOPMed rs1383370732, gnomAD rs1383370732, REVEL 0.01, CADD 18.70
- Q32E (p.Gln32Glu), gnomAD 6-128883339-C-G, REVEL 0.03, CADD 14.80
- Q32K (p.Gln32Lys), gnomAD 6-128883339-C-A, REVEL 0.03, CADD 16.30
- Q32L (p.Gln32Leu), gnomAD 6-128883340-A-T, REVEL 0.01, CADD 14.20
- Q32R (p.Gln32Arg), gnomAD 6-128883340-A-G, REVEL 0.01, CADD 11.80
- Q32P (p.Gln32Pro), gnomAD 6-128883340-A-C, REVEL 0.01, CADD 13.20
- Q32Q (p.Gln32Gln), gnomAD 6-128883341-G-A, CADD 9.83
- A33E (p.Ala33Glu), rs750280423, ClinGen CA3992208, NCI-TCGA Cosmic COSV7035, cosmic curated COSV70350, REVEL 0.11, CADD 22.60, Uncertain significance, Inborn genetic diseases; Congenital muscular dystrophy due to partial LAMA2 defi
- A33T (p.Ala33Thr), rs1362087620, NCI-TCGA Cosmic COSV1013, cosmic curated COSV10137, TOPMed rs1362087620, REVEL 0.11, CADD 20.40, Variant assessed as somatic; moderate impact.
- A33V (p.Ala33Val), ExAC rs750280423, TOPMed rs750280423, gnomAD rs750280423, REVEL 0.10, CADD 25.00, Uncertain significance
- A33S (p.Ala33Ser), gnomAD 6-128883342-G-T, REVEL 0.09, CADD 19.40
- A33A (p.Ala33Ala), rs762858697, gnomAD 6-128883344-A-T, CADD 14.20
- H34Q (p.His34Gln), ExAC rs751547531, TOPMed rs751547531, gnomAD rs751547531, REVEL 0.10, CADD 22.50
- H34R (p.His34Arg), rs398123366, ClinGen CA220737, ClinVar RCV000078744, ClinVar RCV001209509, REVEL 0.11, CADD 22.70, Uncertain significance, LAMA2-related muscular dystrophy; not provided
- H34Y (p.His34Tyr), rs374090280, ClinGen CA3992210, ClinVar RCV002761606, ESP rs374090280, REVEL 0.16, CADD 21.20, Uncertain significance, LAMA2-related muscular dystrophy
- H34H (p.His34His), gnomAD 6-128883347-T-C, CADD 15.10
- Q35* (p.Gln35Ter), Ensembl rs1209404142
- Q35K (p.Gln35Lys), gnomAD 6-128883348-C-A, REVEL 0.05, CADD 23.90
- Q35R (p.Gln35Arg), gnomAD 6-128883349-A-G, REVEL 0.06, CADD 23.80
- Q35L (p.Gln35Leu), gnomAD 6-128883349-A-T, REVEL 0.05, CADD 24.30
- Q35Q (p.Gln35Gln), gnomAD 6-128883350-G-A, CADD 13.90
- Q35H (p.Gln35His), gnomAD 6-128883350-G-T, REVEL 0.06, CADD 23.60
- Q36* (p.Gln36Ter), rs1360796756, ClinGen CA365828360, ClinVar RCV000667526, ClinVar RCV003736880, CADD 40.00, Pathogenic
- Q36E (p.Gln36Glu), gnomAD rs1360796756, REVEL 0.05, CADD 22.50, Pathogenic
- Q36K (p.Gln36Lys), gnomAD 6-128883351-C-A, REVEL 0.08, CADD 22.90
- Q36R (p.Gln36Arg), gnomAD 6-128883352-A-G, REVEL 0.10, CADD 23.20
- R37G (p.Arg37Gly), ExAC rs754399459, REVEL 0.13, CADD 25.80
- R37I (p.Arg37Ile), NCI-TCGA Cosmic COSV7034, cosmic curated COSV70342, REVEL 0.13, CADD 33.00, Variant assessed as somatic; moderate impact.
- R37K (p.Arg37Lys), gnomAD rs1775923680, REVEL 0.10, CADD 24.20
- G38R (p.Gly38Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G38S (p.Gly38Ser), rs2482367554, ClinGen CA365828372, ClinVar RCV003990106, REVEL 0.21, CADD 36.00, Uncertain significance, Merosin deficient congenital muscular dystrophy
- G38C (p.Gly38Cys), gnomAD 6-128883357-G-T, REVEL 0.43, CADD 38.00
- G38D (p.Gly38Asp), gnomAD 6-129049918-G-A, REVEL 0.54, CADD 33.00
Public LAMA2 analysis runs
- LAMA2 analysis run — LAMA2 (4,740 variants) — completed 2026-08-21